Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel plus Zactima (vandetanib) vs docetaxel plus placebo in advanced NSCLC
jRCT2080220351Phase 3
- Sponsor
- AstraZeneca
- Start
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Docetaxel + Zactima (vandetanib) with Docetaxel + placebo (2 arms).
02
Drugs
vandetanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080220351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220351.